Section: New Results

The blood production system

Participants : Mostafa Adimy, Arnaud Ducrot.

Optimization of the treatment of the Chronic Myeloid Leukemia by Imatinib

Imatinib is the main treatment of the Chronic Myeloid Leukemia (CML), with posology varying from 400 to 1000 mg per day. Some affected individuals respond to the treatment with various levels being hematologic, cytogenetic and molecular. The treatment fails in two cases. In the first case, the patient takes a long time to react, then suboptimal response occurs. In the second case, the patient resists after an initial response. We approach the effects of therapy as an optimal control problem to minimize the cost of treatment and the level of leukemic cells. Suboptimal response, resistance and recovery forms are obtained through the influence of imatinib onto the division and mortality rates of leukemic cells.

CML dynamics: optimal control in an age-structured stem cell population

We build an age-structured model for the growth of hematopoietic stem cells HSC in case of CML. Imatinib treatment is analyzed as an optimal control problem. The control represents the drug dosage over a fixed treatment period. We show that optimal control is maximal at the beginning of treatment and declines over time for patients in initial stages of the disease. This work has been submitted to Mathematics and Computers in Simulation.